



A+ Science Newsletter, October 2018

" Unity is strength... when there is teamwork and collaboration, wonderful things can be achieved.

Mattie Stepanek

Only eight weeks to Christmas, unbelievable! Not too long ago we were enjoying the summer season. Time goes by too fast. This in mind, we would like to remind all our readers that it is time to start planning for the coming year. If you are planning to conduct a clinical trial, contact us to hear more about how we can help and guide you and your team. We will assist you with a personalized and cost-efficient solution.

It's important for A+ Science to be able to offer the best possible tools in every clinical trial. Since September 2018, we are happy to be working together with SAGA Diagnostics, a cancer genomics company with unique ultrasensitive technologies for monitoring circulating tumour DNA to stratify patients and follow tumour response using simple blood samples and other "liquid biopsies."

"All cancers release fragments of DNA into surrounding body fluids which can be measured by our methods and provides an excellent non-invasive and quantitative readout of the disease state. Our ctDNA tests are up to 100-fold more sensitive than any other available method, which means we can stratify patients earlier and detect meaningful responses with greater lead time. Thus, our testing services can add valuable genomic information and insights to any oncology clinical trial and increase the overall efficiency of drug development pipelines," says Lao Saal, CEO of SAGA Diagnostics.

Contact us to hear more about this collaboration.

Autumn is a very active conference season, the next conference we are looking forward to is BioEurope 5-7 November in Copenhagen, Denmark.



For more information about our services, visit <u>www.a-plusscience.com</u>

Our vision is to become the CRO best known for its unique and dedicated personnel with focus on customer satisfaction. To Earn Trust- Make Difference.